(Q85579065)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26166806%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

title

State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26166806%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

1 reference

3

Bradley J Monk

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26166806%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

2

Anil K Sood

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26166806%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

author name string

Whitney Graybill

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26166806%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Robert L Coleman

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26166806%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

publication date

9 July 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26166806%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26166806%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

volume

138

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26166806%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26166806%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

page(s)

223-226

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26166806%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

cites work

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.07.008

Conditional survival in ovarian cancer: results from the SEER dataset 1988-2001.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.07.008

Revisiting the complexity of the ovarian cancer microenvironment--clinical implications for treatment strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.07.008

A phase 3 trial of bevacizumab in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.07.008

Incorporation of bevacizumab in the primary treatment of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.07.008

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.07.008

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.07.008

Incorporation of pazopanib in maintenance therapy of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.07.008

New biological treatments for gynecological tumors: focus on angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.07.008

Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.07.008

Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.07.008

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.07.008

The expression of VEGF and Dll4/Notch pathway molecules in ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.07.008

Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.07.008

Notch3 pathway alterations in ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.07.008

Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.07.008

New ways to successfully target tumor vasculature in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.07.008

Tumor-associated macrophages: from mechanisms to therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.07.008

7 January 2021

Inflammation and cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.07.008

The regulation of angiogenesis by tissue cell-macrophage interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.07.008

Therapeutic strategies for targeting the ovarian tumor stroma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.07.008

Tumour-educated macrophages promote tumour progression and metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.07.008

Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.07.008

Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.07.008

Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.07.008

Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.07.008

CSF-1R inhibition alters macrophage polarization and blocks glioma progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.07.008

Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.07.008

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.07.008

MicroRNA regulation in angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.07.008

Regulation of Metastasis by microRNAs in Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.07.008

MiR-718 represses VEGF and inhibits ovarian cancer cell progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.07.008

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.07.008

Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.07.008

10.1016/J.YGYNO.2015.07.008

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26166806%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

1 reference